Galmed Pharmaceuticals
GLMD
25 hedge funds and large institutions have $35.4M invested in Galmed Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 8 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
45% more capital invested
Capital invested by funds: $24.5M → $35.4M (+$10.9M)
0.01% more ownership
Funds ownership: 0.19% → 0.19% (+0.01%)
19% less funds holding
Funds holding: 31 → 25 (-6)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.6M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$892K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$675K |
| 4 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$277K |
| 5 |
Renaissance Technologies
New York
|
+$177K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$2.71M |
| 2 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$327K |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$154K |
| 4 |
VC
Voss Capital
Houston,
Texas
|
-$120K |
| 5 |
Squarepoint
New York
|
-$119K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
26
683 Capital Management
New York
| – | -$2.71M | -4,343 | Closed |
|
|
RCG
27
Rock Creek Group
Washington,
District of Columbia
| – | -$327K | -525 | Closed |
|
|
28
Squarepoint
New York
| – | -$119K | -191 | Closed |
|
29
Millennium Management
New York
| – | -$82K | -131 | Closed |
|
30
Goldman Sachs
New York
| – | -$62K | -99 | Closed |
|
|
TSS
31
Two Sigma Securities
New York
| – | -$57K | -91 | Closed |
|
32
JP Morgan Chase
New York
| – | -$8K | -13 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$5K | -9 | Closed |
|
GLMD Hedge Fund Activity: Q2 2020 in Review
25 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2020, worth a combined $35.4M — up 45% from $24.5M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GLMD and 2 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 8 added.
The largest buyer was Nantahala Capital Management, adding an estimated $3.6M. The largest seller was 683 Capital Management, exiting entirely with an estimated $2.71M sold.
- 25 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2020, down from 31 in Q1 2020.
- Funds reported $35.4M of Galmed Pharmaceuticals stock for Q2 2020, up 45% quarter-over-quarter.
- 2 funds opened new Galmed Pharmaceuticals positions in Q2 2020 and 8 closed out, a net change of -6 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2020 was Nantahala Capital Management, an estimated $3.6M added.
- The largest Galmed Pharmaceuticals seller in Q2 2020 was 683 Capital Management, an estimated $2.71M sold.
Based on aggregated 13F filings for Q2 2020.